



Correction of announcement on stabilization measures in OssDsign AB (publ) during the period from June 10 to June 14, 2019

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, OR OTHER COUNTRIES WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE PERMITTED OR REQUIRE REGISTRATION OR OTHER MEASURES

In the press release on stabilization measures during the period June 10 to June 14, 2019, which was published on June 14, inaccurate stabilization transactions were reported for June 14. OssDsign AB (publ) ("OssDsign" or the "Company") announces correct stabilization information for the period below.

Stabilization information

Issuer: OssDsign AB (publ)

Securities: Shares (ISIN SE0012570448)

Offer size: 6,325,000 shares of which stabilization constitutes a maximum of 825,000 shares

Offer price: 27.50 SEK per share

Ticker: OSSD

Stabilization manager: Erik Penser Bank AB (publ)

Below is a summary of the stabilization transactions that have been undertaken during the period from June 10 to June 14, 2019. All transactions during the stabilization period have been undertaken on Nasdaq First North.

Stabilization transactions

Date	Quantity	Price (volume weighted average)	Price (lowest)	Price (highest)	Marketplace
2019-06-10	18,600	23.9376	23.600	24.000	Nasdaq First North
2019-06-11	16,374	22.8815	22.600	23.400	Nasdaq First North
2019-06-12	0	0.000	0.000	0,000	Nasdaq First North
2019-06-13	1,452	22.800	22.800	22.800	Nasdaq First North
2019-06-14	11,150	23.1112	23.000	23.200	Nasdaq First North

Certified Adviser

The Company's Certified Adviser is Erik Penser Bank AB. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se.

For further information, please contact:

Anders Lundqvist, CEO, OssDsign AB

Tel: +46 73 206 98 08, email: al@ossdsign.com

About OssDsign

OssDsign is a Swedish medical technology company that develops and manufactures regenerative implants for improved healing of bone defects. Providing neuro and plastic surgeons with innovative implants, OssDsign improves the outcome for patients with severe cranial and facial defects worldwide. By combining clinical knowledge with proprietary technology, OssDsign manufactures and sells a growing range of patient-specific solutions for treating cranial defects and facial reconstruction. OssDsign's technology is the result of collaboration between clinical researchers at Karolinska University Hospital in Stockholm and material scientists at the Ångström Laboratory at Uppsala University.

This information is information that OssDsign AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 12:00 CET on June 18, 2019